[1]魏　巍a,张　旭a,李婉娇a,等.临床甲亢和亚临床甲亢患者血清 Nrg4，TSK水平与血脂、甲状腺激素和基础代谢率的相关性分析[J].现代检验医学杂志,2022,37(01):38-42.[doi:10.3969/j.issn.1671-7414.2022.01.008]
　WEI Weia,ZHANG Xua,LI Wan-jiaoa,et al.Correlation Analysis of Serum Nrg4, TSK Levels with Blood Lipids, Thyroid Hormones and Basal Metabolic Rate in Patientswith Clinical Hyperthyroidism and Subclinical Hyperthyroidism[J].Journal of Modern Laboratory Medicine,2022,37(01):38-42.[doi:10.3969/j.issn.1671-7414.2022.01.008]
点击复制

临床甲亢和亚临床甲亢患者血清 Nrg4，TSK水平与血脂、甲状腺激素和基础代谢率的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年01期
页码:
38-42
栏目:
论　著
出版日期:
2022-01-15

文章信息/Info

Title:
Correlation Analysis of Serum Nrg4, TSK Levels with Blood Lipids, Thyroid Hormones and Basal Metabolic Rate in Patientswith Clinical Hyperthyroidism and Subclinical Hyperthyroidism
文章编号:
1671-7414（2022）01-038-06
作者:
魏　巍a; 张　旭a; 李婉娇a; 宋禹青a; 罗　莎a; 张　皓b
（黑龙江省红十字医院/ 森工总医院a. 内分泌代谢科 ;b. 普外科, 哈尔滨 150040)
Author(s):
WEI Weia;  ZHANG Xua;  LI Wan-jiaoa;  SONG Yu-qinga;  LUO Shaa;  ZHANG Haob
（a.Department of Endocrinology and Metabolism;b. Department of General Surgery,Heilongjiang Red Cross Hospital / Sengong General Hospital， Harbin, 150040，China）
关键词:
甲状腺功能亢进症; 亚临床甲状腺功能亢进症; 神经调节蛋白 4; Tsukushi; 血脂; 甲状腺激素; 基础代谢率
分类号:
R582；R575.7；R392.11
DOI:
10.3969/j.issn.1671-7414.2022.01.008
文献标志码:
A
摘要:
目的　探讨临床甲状腺功能亢进症（ hyperthyroidism,HT）、亚临床甲状腺功能亢进症（简称亚甲亢）患者血清神经调节蛋白 4（Nrg4）、Tsukushi（TSK）水平与血脂、甲状腺激素、基础代谢率（ basal metabolic rate,BMR）的相关性。方法　纳入黑龙江省红十字（森工总）医院 2018年 12月～ 2020年 12月收治的 HT患者 150例、亚甲亢患者 130例分别作为 HT组、亚甲亢组，选取同期该院体检的健康志愿者 80例作为表观健康组。比较三组血清 Nrg4， TSK水平以及血脂指标 [总胆固醇（ TC）、三酰甘油（ TG）、低密度脂蛋白胆固醇（ LDL-C）、高密度脂蛋白胆固醇（HDL-C）]、甲状腺激素指标 [TSH、甲状旁腺素（ PTH）、游离甲状腺素（ FT4）、游离三碘甲状腺原氨酸（ FT3）、总三碘甲状腺原氨酸（ TT3），总甲状腺素（ TT4）]和 BMR，分析患者血清 Nrg4，TSK水平与血脂、甲状腺激素、 BMR的相关性，观察血清 Nrg4与 TSK的相关性。结果　HT组血清 Nrg4，TSK，PTH，FT4，FT3，TT3，TT4和 BMR高于亚甲亢组（ t=9.591～ 29.295，均 P＜ 0.05）和表观健康组（ t=11.543～ 26.872，均 P＜ 0.05），而血清 TSH，TC， TG，LDL-C和 HDL-C水平低于亚甲亢组（ t=3.776～ 27.429，均 P＜ 0.05）和表观健康组（ t=3.531～ 17.533，均 P＜ 0.05）,差异均有统计学意义。亚甲亢组血清 Nrg4，TSK水平高于表观健康组（ t=5.277，7.008，均 P＜ 0.05），但 HDL-C， TSH水平低于表观健康组（ t=10.358，28.220，均 P＜ 0.05），差异均有统计学意义。 Pearson线性相关分析提示 HT患者血清 Nrg4，TSK水平与血清 TC，LDL-C，HDL-C和 TSH水平呈负相关（ r=-0.652～ -0.371，均 P＜ 0.05），与血清 PTH，FT4，FT3，TT3，TT4及 BMR呈正相关（ r=0.349～ 0.593，均 P＜ 0.05）；亚甲亢患者血清 Nrg4，TSK水平与 HDL-C，TSH水平呈负相关（ r=-0.615～ -0.489，均 P＜ 0.05）；HT，亚甲亢患者血清 Nrg4与 TSK水平均呈正相关（r=0.581，0.563，均 P＜ 0.05）。结论　针对性别、年龄、吸烟史、饮酒史混杂因素进行校准，并将上述因素剔除后发现 HT，亚甲亢患者血清 Nrg4，TSK水平均增高，且 HT患者的 Nrg4，TSK与血脂、甲状腺激素和 BMR有明显相关性，而亚甲亢患者的 Nrg4，TSK仅与 HDL-C，TSH有关。
Abstract:
Objective　To investigate the correlation between serum neuregulin 4 (Nrg4), tsukushi (TSK) levels and blood lipid,thyroid hormone, basal metabolic rate (BMR) in patients with clinical hyperthyroidism (HT) and subclinical hyperthyroidism(hereinafter referred to as sub hyperthyroidism). Methods　A total of 150 HT patients and 130 subthyroidism patients who wereadmitted to Heilongjiang Red Cross Hospital from December 2018 to December 2020 were included as HT group andsubthyroidism group, respectively. 80 healthy volunteers who received physical examination in the hospital during the sameperiod were selected as the apparent health group. The serum Nrg4, TSK levels and blood lipids indexes [totalcholesterol (TC), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C)], thyroid hormone indexes [thyroid stimulating hormone (TSH) and parathyroid hormone (PTH) and free thyroxine(FT4), free triiodothyronine (FT3), total triiodothyronine 3 (TT3), total thyroxine (TT4)] and BMR in three groups were compared.The correlation between serum Nrg4 and TSK levels and blood lipid, thyroid hormone and BMR was analyzed, and the correlationbetween serum Nrg4 and TSK was observed. Results　The serum Nrg4, TSK, PTH, FT4, FT3, TT3, TT4 and BMR in HT groupwere higher than those in subthyroidism group(t=9.591~29.295, all P ＜ 0.05), and apparent health group(t=11.543~26.872, all P＜ 0.05), while the serum TSH, TC, TG, LDL-C and HDL-C levels were lower than those in subthyroidism group(t=3.776~27.429,all P ＜ 0.05), and apparent health group (t=3.531~17.533, all P ＜ 0.05)，the difference were statistically significant, respectively.The serum Nrg4 and TSK levels in subthyroidism group were higher than those in apparent health group(t=5.277, 7.008, all P＜ 0.05), but the HDL-C and TSH levels were lower than those in apparent health group (t=10.358, 28.220, all P ＜ 0.05) ，thedifference were statistically significant, respectively. Pearson linear correlation analysis showed that serum Nrg4, TSK levels werenegatively correlated with serum TC, LDL-C, HDL-C and TSH levels in HT patients(r=-0.652~-0.371, all P ＜ 0.05), andpositively correlated with serum PTH, FT4, FT3, TT3, TT4 and BMR (r=0.349~0.593, all P ＜ 0.05). The serum Nrg4 and TSKlevels were negatively correlated with the HDL-C and TSH levels in subthyroidism patients (r=-0.615~-0.489, all P ＜ 0.05).Serum Nrg4 and TSK levels were positively correlated in HT and subthyroidism patients (r=0.581, 0.563, all P ＜ 0.05).Conclusion　The confounding factors such as gender, age, smoking history and drinking history were adjusted. After eliminatingthe above factors, it was found that serum Nrg4 and TSK levels in patients with HT and hypothyroidism were increased, and Nrg4,TSK and blood lipids, thyroid hormones and BMR in HT patients were significantly increased. Correlation, while Nrg4 and TSKin patients with hypothyroidism were only related to HDL-C and TSH.

参考文献/References:

[1] TAYLOR P N,ALBRECHT D, SCHOLZ A, etal. Global epidemiology of hyperthyroidism andhypothyroidism[J]. Nature Reviews Endocrinology,2018, 14(5): 301-316.
[2] 狄正霞，田文君，邵俊峰，等．体检人群甲状腺功能异常的调查研究[J]．检验医学与临床，2019，16（9）：1172-1175．DI Zhengxia, TIAN Wenjun, SHAO Junfeng, et al.Investigation on thyroid dysfunction in physicalexamination population[J]. Laboratory Medicine andClinic, 2019, 16(9):1172-1175.
[3] 陈国芳，刘超. 亚临床甲状腺疾病的新挑战：从指南到实践[J]. 中华内分泌代谢杂志，2017，33(1):88-90.CHEN Guofang, LIU Chao. New challenge insubclinical thyroid disease： from guideline to practice[J]. Chinese Journal of Endocrinology and Metabolism,2017, 33(1):88-90.
[4] LISTED N. Calcium metabolism and bone inhyperthyroidism[J]. Lancet(London,England), 2018,2(7686): 1300-1302.
[5] 孙爽，高燕燕．神经调节蛋白4 与代谢疾病关系的研究进展[J]．齐鲁医学杂志，2017，32(5)：622-623.SUN Shuang, GAO Yanyan. Research progress on therelationship between neuromodulin 4 and metabolicdiseases[J]. Medical Journal of Qilu, 2017,32(5):622-623.
[6] AHMAD S, ANAM M B, ITO N, et al. Involvement oftsukushi in diverse developmental processes[J]. Journalof Cell Communication and Signaling, 2018, 12(1):205-210.
[7] 刘志民，冯晓云，邹俊杰．甲状腺功能亢进症[M].2版. 北京: 中国医药科技出版社, 2013：84．LIU Zhimin, FENG Xiaoyun, ZOU Junj ie.Hyperthyroidism[M]. 2th Ed.Beijing: China Medicaland Technology Press, 2013:84.
[8] 中华医学会内分泌学分会,《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南- 甲状腺疾病的实验室及辅助检查[J]. 中华内科杂志, 2007,46(8):697-702.Endocrinology Branch of Chinese Medical Association,Compilation Group of Chinese Guidelines forDiagnosis and Treatment of Thyroid Diseases. Chineseguidelines for diagnosis and treatment of thyroiddiseases-laboratory and auxiliary examinationsof thyroid diseases[J].Chinese Journal of InternalMedicine, 2007, 46(8):697-702.
[9] 孙健，罗苏珊，乔凯，等．甲状腺功能亢进性周期性麻痹的研究现状与进展[J]．中国临床神经科学,2017, 25(1):98-104.SUN Jian, LUO Sushan, QIAO Kai, et al. Researchprogress of thyrotoxic periodic paralysis [J]. ChineseJournal of Clinical Neurosciences, 2017, 25(1):98-104.
[10] 卢振华，马勇翔，张靖，等．甲状腺功能亢进相关心血管疾病的研究进展[J]．中国医师杂志，2019，21（10）：1588-1591．LU Zhenhua, MA Yongxiang, ZHANG Jing, et al. Theresearch on hyperthyroidism cardiovascular diseases [J].Journal of Chinese Physician, 2019, 21(10):1588-1591.
[11] 张艳，李鸿钏，刘翔，等．甲状腺疾病应用参考变化因子评估连续监测甲状腺功能指标结果的价值[J]. 现代检验医学杂志，2019, 34(5):135-138.ZHANG Yan, LI Hongchuan, LIU Xiang, et al. Valueof using reference change factor to evaluate the resultsof continuous monitoring of thyroid function indicatorsin thyroid diseases [J]. Journal of Modern LaboratoryMedicine, 2019, 34(5):135-138.
[12] 程贤鹦，何银辉．神经调节蛋白4 在肥胖及代谢性疾病作用的研究进展[J]．中华临床医师杂志（电子版）,2019, 13(9):684-688.CHENG Xianying, HE Yinhui. Role of neuregulin 4 inobesity and metabolic disease [J]. Chinese Journal ofClinicians(Electronic Edition), 2019, 13(9):684-688.
[13] OHTA K, AOYAMA E, AHMAD S, et al. CCN2/CTGF binds the small leucine rich proteoglycan proteinTsukushi[J]. Journal of Cell Communication andSignaling, 2019, 13(1): 113-118.
[14] 杨帆，李晓南．神经调节蛋白4 生物学功能的研究进展[J]．生理学报, 2017, 69(3):351-356.YANG Fan, LI Xiaonan. Research progress of neuregulin4 biological function [J]. Acta Physiologica Sinica,2017, 69(3):351-356.
[15] 钟筑宁，罗丽丽，肖文革，等．关于甲亢患者肝功能异常的临床观察[J]．贵州医药, 2017, 41(3):289-290.ZHONG Zhuning, LUO Lili, XIAO Wenge, et al.Clinical observation on abnormal liver function inpatients with hyperthyroidism[J]. Guizhou MedicalJournal, 2017, 41(3):289-290.
[16] ACHARJEE U K, GEJIMA R, FELEMBAN A M, et al.Tsukushi expression is dependent on Notch signalingand oscillated in the presomitic mesoderm duringchick somitogenesis[J]. Biochemical and BiophysicalResearch Communications, 2015, 465(3): 625-630.
[17] 余成强，李步荣，何家花，等．陕西省商洛地区孕早期妇女甲状腺功能参考范围的初步建立和应用研究[J]．现代检验医学杂志，2020，35（2）：139-141, 156.YU Chengqiang, LI Burong, HE Jiahua, et al.Preliminary study on thyroid function reference rangesof pregnant women during early pregnancy in Shangluo[J]. Journal of Modern Laboratory Medicine, 2020,35(2):139-141,156.
[18] 段文冰，刘芸，张璐璐，等．亚临床甲功异常患者血脂、HCY、血常规与甲功指标的相关分析[J]．新医学，2018，49（1）：42-46．DUAN Wenbing, LIU Yun, ZHANG Lulu, et al.Correlation analysis of blood lipid, homocysteine,blood routine test and thyroid function parameters inpatients with subclinical thyroid dysfunction [J]. NewMedicine, 2018, 49(1):42-46.
[19] 段秋琴，陈桂金，王玉月．甲状腺功能亢进症患者治疗前、后血清骨代谢、钙磷代谢水平和甲状腺功能变化及其临床意义[J]．广西医科大学学报, 2019,36(9):1480-1483.DUAN Qiuqin, CHEN Guijin, WANG Yuyue. Changesof serum CT, PTH and BGP levels and thyroidfunction and their clinical significance in patients withhyperthyroidism before and after treatment [J]. Journalof Guangxi Medical University, 2019, 36(9):1480-1483.
[20] MOORADIAN A D. Age-related resistance to thyroidhormone action[J]. Drugs & Aging, 2019, 36(11): 1007-1014.
[21] 迟玉娥．甲状腺功能亢进症对糖代谢和胰岛素分泌功能的影响[J]．中国实验诊断学,2018, 22(2):213-215.CHI Yu’e. Effects of hyperthyroidism on glucosemetabolism and insulin secretion[J]. Chinese Journal ofLaboratory Diagnosis,2018, 22(2):213-215.
[22] 滕卫平．甲状腺疾病诊治现代进展[J]．中国实用内科杂志, 2019, 39(4):311-315.TENG Weiping. A collection of update in the thyroiddiseases [J]. Chinese Journal of Practical InternalMedicine, 2019, 39(4):311-315.
[23] LI Min,CHEN Ying,JIANG Jingjing, et a l .Elevated serum neuregulin 4 levels in patients withhyperthyroidism[J]. Endocrine Connections, 2019,8(6): 728-735.
[24] LIU Deying, ZHANG Peizhen, WEI Xueyun, etal. Elevated serum Tsukushi levels in patients withhyperthyroidism[J]. Frontiers in Endocrinology, 2020,11: 580097.

备注/Memo

备注/Memo:
基金项目：2018 年黑龙江省自然科学基金项目（H20180061）。
作者简介：魏巍（1979-），女，硕士研究生，主治医师，研究方向：甲状腺疾病，E-mail:iceberg126126@126.com。
通讯作者：张皓，男，E-mail:190551142@qq.com。
更新日期/Last Update: 1900-01-01